{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:10:32Z","timestamp":1791407432867,"version":"4.3.3"},"reference-count":59,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Structured medication reviews (SMRs) were introduced into the National Health Service (NHS) Primary Care to support the delivery of the NHS Long\u2010Term Plan for medicines optimization. SMRs improve the quality of care, reduce harm and offer value for money. However, evidence to support SMRs for patients with chronic kidney disease (CKD) stage G4\u20105D with elevated risk of cardiovascular disease and premature mortality is unknown. This scoping review aimed to assess the extent and nature of SMR research in the population of patients with CKD stage G4\u20105D. Electronic databases were searched on 20 October 2023. Studies were eligible if they described an SMR in adults with CKD stage G4\u20105D, regardless of the study design. Data detailing the global patterns, population and intervention descriptions, professionals performing SMR, and reported areas for future research were extracted. The extracted outcome data were categorized as clinical, patient\u2010important, medication\u2010related and experience\u2010related. A narrative synthesis was completed. Seventeen studies (81%) were conducted in nephrology outpatient settings, three (14%) during acute hospital admissions and one (5%) within the community pharmacy. Eighteen studies (86%) were quantitative, including five randomized controlled trials. Ten (48%) studies were undertaken in the United States and Canada, and two in Europe (France and Norway). No such studies have been conducted in the United Kingdom. Our review revealed that there is a lack of evidence for SMR as a strategy to reduce polypharmacy and harms from medication for adults with CKD stage G4\u20105D. Therefore, further research is required in this area.<\/jats:p>","DOI":"10.1111\/bcp.16363","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T02:03:21Z","timestamp":1735610601000},"page":"1132-1156","source":"Crossref","is-referenced-by-count":5,"title":["Medication review interventions for adults living with advanced chronic kidney disease: A scoping review"],"prefix":"10.1111","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-2797","authenticated-orcid":false,"given":"Cathy Margaret","family":"Pogson","sequence":"first","affiliation":[{"name":"Pharmacy Department Portsmouth Hospitals University NHS Trust  Portsmouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-4836","authenticated-orcid":false,"given":"Rosalynn","family":"Austin","sequence":"additional","affiliation":[{"name":"Department of Public Health, Faculty of Health Sciences University of Stavanger  Stavanger Norway"},{"name":"Cardiology Department Portsmouth Hospitals University NHS Trust  Portsmouth UK"},{"name":"NIHR Applied Research Collaborative Wessex Innovation Centre  Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-8294","authenticated-orcid":false,"given":"Jignesh Prakash","family":"Patel","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, Faculty of Life Sciences &amp; Medicine Kings College London  London UK"},{"name":"Department of Haematological Medicine King's College Hospital Foundation NHS Trust  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0745-3478","authenticated-orcid":false,"given":"David Collins","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Medication without harm","year":"2017"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx134"},{"key":"e_1_2_10_4_1","volume-title":"Polypharmacy and medicines optimisation: making it safe and sound","author":"Duerden M","year":"2013"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.34067\/kid.0000000000000447"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000518454"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102020\u2010042548"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz046"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255\u2010023\u201003516\u20101"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.228"},{"key":"e_1_2_10_11_1","volume-title":"RRT and conservative management. Evidence review for coordinating care","author":"Renal Replacement Therapy Guideline Committee","year":"2018"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000520028"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa064"},{"key":"e_1_2_10_14_1","volume-title":"The report of the Short Life Working Group on reducing medication\u2010related harm","author":"Acute Care and Workforce\/Acute Care and Quality\/CQC","year":"2018"},{"key":"e_1_2_10_15_1","volume-title":"Overview: multimorbidity: clinical assessment and management: guidance","author":"Multimorbidity Guideline Committee","year":"2016"},{"key":"e_1_2_10_16_1","volume-title":"Overview: medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence: guidance","author":"Medication Adherence Guideline Committee","year":"2009"},{"key":"e_1_2_10_17_1","volume-title":"Structured medication reviews and medicines optimisation","author":"NHS England","year":"2020"},{"key":"e_1_2_10_18_1","volume-title":"Scoping reviews (2020). JBI Manual for evidence synthesis","author":"Peters M","year":"2024"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.16363","volume-title":"Medication review interventions for adults living with advanced chronic kidney disease: a scoping review","author":"Pogson C.","year":"2024"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18\u20100850"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16181"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16177"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16178"},{"issue":"2","key":"e_1_2_10_24_1","first-page":"117","article-title":"Evaluation of drug\u2010related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist","volume":"47","author":"Grabe DW","year":"1997","journal-title":"Clin Nephrol"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp\u2010journals\u201010071\u201023919"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/2054358120954028"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijpp.12674"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13936"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxac190"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000229"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18084370"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.12.002"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1590\/2175\u20108239\u2010jbn\u20102019\u20100205"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010019\u201002727\u20109"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jppr.1539"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/20543581221098778"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.02.374"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542\u20104758.2009.00328.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.4103\/1319\u20102442.239639"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.5301\/jn.5000063"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010012\u20109748\u20106"},{"issue":"1297","key":"e_1_2_10_42_1","first-page":"25","article-title":"Implementation of a pharmacist medication review clinic for haemodialysis patients","volume":"122","author":"Mirkov S","year":"2009","journal-title":"N Z Med J"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010017\u20100528\u20101"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.06790617"},{"key":"e_1_2_10_45_1","volume-title":"Overview: medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes: guidance","author":"Medicines Optimisation Guideline Committee","year":"2015"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2061"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.11.006"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2400248"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2286321"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12453"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2024.01.016"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581\u2010024\u201000823\u20103"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp20x714125"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2010.06.004"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010023\u201001039\u2010z"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010020\u201000747\u20100"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15759"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.6102"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_2_10_60_1","volume-title":"Room for review: a guide to medication review. The agenda for patients, practitioners and managers","author":"Shaw J","year":"2002"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T09:42:57Z","timestamp":1744450977000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/bcp.16363"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16363","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}